Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open-label phase 3 trial
Julie Renee Brahmer, Delvys Rodríguez‐Abreu, Andrew George Robinson et al. · The Lancet Oncology · 2017
Cited by 348 works. doi:10.1016/s1470-2045(17)30690-3
Authors
- Julie Renee Brahmer
- Delvys Rodríguez‐Abreu
- Andrew George Robinson
- Rina Hui
- Tibor Csőszi
- Andrea Fülöp
- Maya Gottfried
- Nir Peled
- Ali Tafreshi
- Sinead D. Cuffe
- Mary E.R. O'Brien
- Suman Rao
- Katsuyuki Hotta
- Jin Zhang
- Gregory M. Lubiniecki
- Anne C. Deitz
- Reshma A. Rangwala
- Martin Reck
References
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- Multiple Imputation for Nonresponse in Surveys
- The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in Oncology
- Analysis of Incomplete Multivariate Data
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
- Analysis of Incomplete Multivariate Data
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
- Interpreting the significance of changes in health-related quality-of-life scores.
- Crizotinib versus Chemotherapy in Advanced ALK -Positive Lung Cancer